Agile Therapeutics Inc., a company dedicated to women's healthcare, is making significant strides in the world of prescription contraceptive products. The New Jersey-based company is researching, developing, and commercializing these products specifically for women living in the United States. Their pioneering product, Twirla, also known as AG200-15, is a revolutionary once-weekly prescription combination hormonal contraceptive patch. Agile Therapeutics is also currently hard at work developing a pipeline of Twirla line extensions and other exciting products, such as the AG200-15 Extended Regimen (ER), which permits women to have four episodes of withdrawal bleeding per year; the AG200-15 smaller patch (SmP), which provides shorter and lighter withdrawal bleeds and enhances contraceptive efficacy; AG200-15 ER SmP, which provides an opportunity for women to extend the length of their contraceptive cycle while also experiencing shorter and lighter withdrawal bleeding episodes per year; and the P-Patch, a progestin-only contraceptive patch intended for women who are either unable or unwilling to take estrogen. Agile Therapeutics was founded in 1997 and has since become a leading authority in women's healthcare, with its headquarters based out of Princeton, New Jersey.
Agile Therapeutics's ticker is AGRX
The company's shares trade on the NASDAQ stock exchange
They are based in Princeton, New Jersey
There are 11-50 employees working at Agile Therapeutics
It is agiletherapeutics.com
Agile Therapeutics is in the Healthcare sector
Agile Therapeutics is in the Drugs - Generic industry
The following five companies are Agile Therapeutics's industry peers: